Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free SIGA Stock Alerts

Siga Technologies (SIGA) Competitors

Siga Technologies logo
$4.64 +0.01 (+0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$4.68 +0.04 (+0.86%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SIGA vs. CRVS, JBIO, AVBP, OLMA, and MPLT

Should you be buying Siga Technologies stock or one of its competitors? The main competitors of Siga Technologies include Corvus Pharmaceuticals (CRVS), Jade Biosciences (JBIO), ArriVent BioPharma (AVBP), Olema Pharmaceuticals (OLMA), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Siga Technologies compare to Corvus Pharmaceuticals?

Siga Technologies (NASDAQ:SIGA) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Siga Technologies has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Siga Technologies$94.57M3.52$23.28M$0.3114.97
Corvus PharmaceuticalsN/AN/A-$15.28M-$0.50N/A

Siga Technologies has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Siga Technologies has a net margin of 24.61% compared to Corvus Pharmaceuticals' net margin of 0.00%. Siga Technologies' return on equity of 11.25% beat Corvus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Siga Technologies24.61% 11.25% 9.98%
Corvus Pharmaceuticals N/A -23.58%-20.60%

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Siga Technologies. MarketBeat recorded 4 mentions for Corvus Pharmaceuticals and 3 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.67 beat Corvus Pharmaceuticals' score of 0.50 indicating that Siga Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Siga Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corvus Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 2.0% of Siga Technologies shares are owned by insiders. Comparatively, 28.5% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 112.31%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Siga Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Corvus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Siga Technologies beats Corvus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Siga Technologies compare to Jade Biosciences?

Siga Technologies (NASDAQ:SIGA) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Siga Technologies has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Siga Technologies$94.57M3.52$23.28M$0.3114.97
Jade BiosciencesN/AN/A-$127.41M-$4.61N/A

Siga Technologies has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Jade Biosciences has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Siga Technologies has a net margin of 24.61% compared to Jade Biosciences' net margin of 0.00%. Siga Technologies' return on equity of 11.25% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Siga Technologies24.61% 11.25% 9.98%
Jade Biosciences N/A -46.55%-42.99%

In the previous week, Jade Biosciences had 1 more articles in the media than Siga Technologies. MarketBeat recorded 4 mentions for Jade Biosciences and 3 mentions for Siga Technologies. Jade Biosciences' average media sentiment score of 0.89 beat Siga Technologies' score of 0.67 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Siga Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jade Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

55.4% of Siga Technologies shares are owned by institutional investors. 2.0% of Siga Technologies shares are owned by company insiders. Comparatively, 24.9% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Jade Biosciences has a consensus target price of $31.17, indicating a potential upside of 23.38%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Siga Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.89

Summary

Siga Technologies and Jade Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Siga Technologies compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 18.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 2.0% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Siga Technologies has a net margin of 24.61% compared to ArriVent BioPharma's net margin of 0.00%. Siga Technologies' return on equity of 11.25% beat ArriVent BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ArriVent BioPharmaN/A -62.49% -58.11%
Siga Technologies 24.61%11.25%9.98%

ArriVent BioPharma has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

In the previous week, ArriVent BioPharma had 3 more articles in the media than Siga Technologies. MarketBeat recorded 6 mentions for ArriVent BioPharma and 3 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.67 beat ArriVent BioPharma's score of 0.09 indicating that Siga Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ArriVent BioPharma
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Siga Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ArriVent BioPharma presently has a consensus target price of $43.00, indicating a potential upside of 44.15%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe ArriVent BioPharma is more favorable than Siga Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ArriVent BioPharma
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Siga Technologies has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ArriVent BioPharmaN/AN/A-$166.31M-$4.41N/A
Siga Technologies$94.57M3.52$23.28M$0.3114.97

Summary

Siga Technologies beats ArriVent BioPharma on 9 of the 16 factors compared between the two stocks.

How does Siga Technologies compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Olema Pharmaceuticals presently has a consensus target price of $44.40, indicating a potential upside of 203.28%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than Siga Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Olema Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Olema Pharmaceuticals has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Siga Technologies has a net margin of 24.61% compared to Olema Pharmaceuticals' net margin of 0.00%. Siga Technologies' return on equity of 11.25% beat Olema Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Olema PharmaceuticalsN/A -42.95% -38.78%
Siga Technologies 24.61%11.25%9.98%

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 16.4% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Olema Pharmaceuticals had 3 more articles in the media than Siga Technologies. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 3 mentions for Siga Technologies. Olema Pharmaceuticals' average media sentiment score of 0.88 beat Siga Technologies' score of 0.67 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Olema Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Siga Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Siga Technologies has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/A-$162.45M-$1.86N/A
Siga Technologies$94.57M3.52$23.28M$0.3114.97

Summary

Olema Pharmaceuticals beats Siga Technologies on 8 of the 15 factors compared between the two stocks.

How does Siga Technologies compare to Maplight Therapeutics?

Siga Technologies (NASDAQ:SIGA) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Siga Technologies has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Siga Technologies$94.57M3.52$23.28M$0.3114.97
Maplight TherapeuticsN/AN/A-$161.15M-$39.65N/A

Maplight Therapeutics has a consensus target price of $34.43, indicating a potential upside of 23.31%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maplight Therapeutics is more favorable than Siga Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Siga Technologies has a net margin of 24.61% compared to Maplight Therapeutics' net margin of 0.00%. Siga Technologies' return on equity of 11.25% beat Maplight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Siga Technologies24.61% 11.25% 9.98%
Maplight Therapeutics N/A N/A N/A

In the previous week, Maplight Therapeutics had 11 more articles in the media than Siga Technologies. MarketBeat recorded 14 mentions for Maplight Therapeutics and 3 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.67 beat Maplight Therapeutics' score of 0.37 indicating that Siga Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Siga Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Maplight Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

55.4% of Siga Technologies shares are held by institutional investors. 2.0% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Siga Technologies beats Maplight Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Siga Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SIGA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SIGA vs. The Competition

Export
MetricSiga TechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$332.78M$3.10B$6.25B$11.87B
Dividend YieldN/A1.91%2.73%5.21%
P/E Ratio14.9718.3729.0428.47
Price / Sales3.52281.31476.6160.94
Price / Cash13.8250.4327.6236.52
Price / Book1.674.339.676.67
Net Income$23.28M$72.19M$3.55B$332.53M
7 Day Performance1.09%2.02%1.70%2.01%
1 Month Performance-11.45%6.41%5.62%9.20%
1 Year Performance-14.07%37.73%34.42%39.59%

Siga Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SIGA
Siga Technologies
1.3998 of 5 stars		$4.64
+0.2%		N/AN/A$332.78M$94.57M14.9740
CRVS
Corvus Pharmaceuticals
3.2316 of 5 stars		$15.67
-1.5%		$33.33
+112.7%		N/A$1.32BN/AN/A30
JBIO
Jade Biosciences
3.2704 of 5 stars		$26.54
-1.2%		$31.17
+17.5%		N/A$1.31BN/AN/A20
AVBP
ArriVent BioPharma
2.7999 of 5 stars		$29.59
-2.4%		$43.00
+45.3%		N/A$1.31BN/AN/A40
OLMA
Olema Pharmaceuticals
2.5347 of 5 stars		$15.02
-1.7%		$44.40
+195.5%		N/A$1.31BN/AN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SIGA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel